PR95301

DUBLIN, Apr. 7, 2022, /PRNewswire=KYODO JBN/--

ERS Genomics Limited (ERS) is pleased to announce a license agreement with

Central Institute for Experimental Animals (CIEA) in Japan. This is a

non-exclusive licensing agreement granting CIEA access to the ERS CRISPR/Cas9

patent portfolio.

ERS, co-founded by Dr. Emmanuelle Charpentier, 2020 Nobel Prize winner for

gene-editing, provides access to the foundational CRISPR/Cas9 intellectual

property. Eighty-nine patents are held in over eighty countries.

CIEA is a private and independent non-profit institute, founded in 1952, with

the aim of contributing to medical care and medical science based on the

ethical use of animals in modelling of diseases and treatments.

CEO, Eric Rhodes had the following statement: ‘“CRISPR/Cas9 is a powerful

genome engineering tool that has revolutionized the arena of biotechnology. At

ERS, we are committed to making our technology accessible and available. We are

pleased to be able to support CIEA, a company recognized worldwide for their

excellence in the development of novel animal models for research.”

CEO of CIEA, Ryuta Nomura had the following to say about how CRISPR/Cas9

technology benefits CIEA’s contributions to healthcare globally: “The progress

and evolution of gene-editing technology has been remarkable. CRISPR/Cas9 has

actually changed not only the methodology but also the way of thinking in the

field of medicine and biology.”

Financial details of the agreement are not disclosed.

About ERS Genomics

ERS Genomics is a biotechnology company based in Dublin, Ireland. The company

was formed to provide broad access to the foundational CRISPR/Cas9 intellectual

property held by Dr. Emmanuelle Charpentier. Non-exclusive licenses are

available for research and sale of products and services across multiple fields

including: research tools, kits, reagents; discovery of novel targets for

therapeutic intervention; cell lines for discovery and screening of novel drug

candidates; GMP production of healthcare products; companion animal and

livestock health; production of industrial materials such as enzymes, biofuels

and chemicals; and synthetic biology.

For additional information, please visit: www.ersgenomics.com　

About Central Institute for Experimental Animals:

Central Institute for Experimental Animals is a private and independent

non-profit institute, founded in Japan in 1952 with the aim of contributing to

medical care and medical science based on animal experiments. CIEA is renowned

for the research, development and commercialization of the world's most

advanced laboratory animals and germ-free animal-related technologies that

provide technologies such as monitoring tests, pathology tests, genetic

modification, developmental engineering, and image analysis. CIEA collaborates

and cooperates with universities and research institutions in Japan and other

countries, international public organizations such as WHO, NIH, FDA, and NIBSC,

and other business enterprises.

For additional information, please visit: www.ciea.or.jp/en/　

Summit Pharmaceuticals International Corporation, a subsidiary of Sumitomo

Corporation, serves as the exclusive agent for ERS Genomics in Japan.

Photo:   https://mma.prnewswire.com/media/1778872/ERS_Genomics_Eric_Rhodes.jpg

Caption: Eric Rhodes, CEO, ERS Genomics

Logo:    https://mma.prnewswire.com/media/1756881/ERS_Genomics_Logo.jpg

Photo:   https://mma.prnewswire.com/media/1778870/Ryuta_Nomura.jpg

Caption: Ryuta Nomura, CEO, CIEA

Logo:    https://mma.prnewswire.com/media/1778871/CIEA_Logo.jpg

Source: ERS Genomics